Tonix Pharmaceuticals (NASDAQ:TNXP) Announces Quarterly Earnings Results

Tonix Pharmaceuticals (NASDAQ:TNXP) posted its quarterly earnings data on Monday. The company reported ($2.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.39) by ($0.50), FiscalAI reports. Tonix Pharmaceuticals had a negative net margin of 420.45% and a negative return on equity of 78.17%. The firm had revenue of $17.23 million for the quarter, compared to analysts’ expectations of $16.32 million.

Here are the key takeaways from Tonix Pharmaceuticals’ conference call:

• TONMYA sales and prescriptions grew: Third-quarter net sales were approximately $15 million, up 37% quarter-over-quarter, while prescriptions rose 28% to 16,375. Management attributed momentum to payer agreements, improved prescription approvals and the expanded 150-person sales force, and said early fourth-quarter trends were continuing.
• TONMYA coverage reached approximately 53% of U.S. covered lives, and the company reported rising refill prescriptions and declining bridge-script reliance. Management said the expanded sales force is reaching a larger share of fibromyalgia prescribers and expects broader access and awareness to support growth.
• Dr. Reddy’s filed a Paragraph IV ANDA challenging TONMYA patents; Tonix said it will defend its intellectual property, which it says currently provides protection into 2034. The company did not provide details on the litigation’s timing or likely outcome.
• Tonix ended September with $162.8 million in cash, down from $207.6 million at year-end, and said cash plus post-quarter equity-offering proceeds should fund operations into early Q3 2027. Quarterly R&D expenses rose to $25.8 million and SG&A to $45.6 million, largely reflecting pipeline development and TONMYA launch costs.
• The company is advancing its pipeline: the HORIZON phase II MDD study is enrolling, the TNX-4800 Lyme-prevention field study is planned to start in 2027, and an investigator-led TNX-1500 kidney-transplant study is expected to begin in early 2027. These programs remain clinical-stage and their timing and outcomes are uncertain.

Tonix Pharmaceuticals Trading Down 8.7%

Shares of NASDAQ:TNXP opened at $4.10 on Wednesday. The company has a fifty day simple moving average of $8.33 and a 200 day simple moving average of $12.07. The firm has a market cap of $70.31 million, a PE ratio of -0.33 and a beta of 1.90. Tonix Pharmaceuticals has a 12-month low of $4.00 and a 12-month high of $20.56.

Insider Buying and Selling

In related news, CEO Seth Lederman acquired 2,000 shares of the firm’s stock in a transaction on Thursday, August 27th. The stock was bought at an average cost of $13.79 per share, with a total value of $27,580.00. Following the acquisition, the chief executive officer directly owned 11,005 shares in the company, valued at approximately $151,758.95. The trade was a 22.21% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 2.00% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Wall Street Zen raised shares of Tonix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, October 4th. Raymond James Financial reiterated a “strong-buy” rating on shares of Tonix Pharmaceuticals in a report on Tuesday, October 20th. Weiss Ratings reissued a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a research report on Monday, October 26th. Finally, Canaccord Genuity Group initiated coverage on Tonix Pharmaceuticals in a research note on Monday, October 26th. They set a “buy” rating and a $18.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $22.33.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company focused on developing therapies for conditions involving the central nervous system, immunology and infectious diseases. The company’s research programs are designed to address disorders with significant unmet medical needs, including chronic pain, neuropsychiatric conditions and infectious diseases. Tonix’s pipeline has included TNX-102 SL, an investigational sublingual formulation of cyclobenzaprine being studied for fibromyalgia and other pain-related conditions.